CARsgen Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
CARsgen Therapeutics Holdings has been growing earnings at an average annual rate of 28.9%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 64.8% per year.
Key information
28.9%
Earnings growth rate
47.5%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | -64.8% |
| Return on equity | -46.4% |
| Net Margin | -10,960.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How CARsgen Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 6 | -695 | 159 | 581 |
| 31 Mar 24 | 3 | -721 | 146 | 620 |
| 31 Dec 23 | 0 | -748 | 133 | 660 |
| 30 Sep 23 | 0 | -834 | 135 | 673 |
| 30 Jun 23 | 0 | -920 | 136 | 686 |
| 31 Mar 23 | 0 | -906 | 136 | 683 |
| 31 Dec 22 | 0 | -892 | 137 | 679 |
| 30 Sep 22 | 13 | -810 | 131 | 660 |
| 30 Jun 22 | 26 | -727 | 126 | 641 |
| 31 Mar 22 | 26 | -2,736 | 126 | 571 |
| 31 Dec 21 | 26 | -4,744 | 127 | 501 |
| 30 Sep 21 | 13 | -4,831 | 124 | 416 |
| 30 Jun 21 | 0 | -4,917 | 121 | 332 |
| 31 Mar 21 | 0 | -2,991 | 99 | 306 |
| 31 Dec 20 | 0 | -1,064 | 78 | 281 |
Quality Earnings: 2171 is currently unprofitable.
Growing Profit Margin: 2171 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2171 is unprofitable, but has reduced losses over the past 5 years at a rate of 28.9% per year.
Accelerating Growth: Unable to compare 2171's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2171 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 2171 has a negative Return on Equity (-46.41%), as it is currently unprofitable.